Another multicenter RCT of 1329 women further demonstrated that individualized FSH dosing based on serum AMH and body weight was non-inferior for ongoing pregnancy and implantation rates as well as the risk of moderate to severe OHSS (45). This evidence concerns the gene BRD2 and ovarian hyperstimulation syndrome.